The AbbVie Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Stronger technical forecast for AbbVie Inc. stock price after Thursday trading. The good news is that AbbVie doesn't have all its eggs in one basket, as it still has Skyrizi, which could be a substitute for Humira, and it's an attractive alternative, as it needs to be injected fewer times. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock. Get the latest AbbVie Inc. ABBV detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. AbbVie stock is both cheap and has an attractive dividend yield. ABBV is lower by -$0.16 from the previous closing price of $99.12 on volume of 4,157,987 shares. Out of 18 analysts, 12 (66.67%) are recommending ABBV as a Strong Buy, 1 (5.56%) are recommending ABBV as a Buy, 5 (27.78%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are … ; AbbVie Inc has risen higher in 5 of those 8 years over the subsequent 52 week period, corresponding to a historical probability of 62 % ; Is AbbVie Inc Stock Undervalued? Get the latest AbbVie Inc. ABBV detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Buy or Sell this stock? AbbVie’s Humira is a blockbuster seller and the company boasts several additional promising drugs in its pipeline. The consensus among 18 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock. If you had invested in AbbVie stock at $35.12, your return over the last 7 years would have been 205.1%, for an annualized return of 17.27%. It sells below 10x earnings, with a 4.9% yield and a 28% upside value. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Earnings reports or recent company news can cause the stock price to drop. And while that's an improvement from 61% the year prior, it's clear that the company needs to become more diversified, especially with sales from Humira dropping by 5% so far this year. Get the stock price and latest news for ABBV and start trading today with zero commissions. Election Stock Watchlist: AbbVie, Amazon, Uber, Lyft. The stock is 30% off its 52-week high, perhaps creating an … AbbVie Inc (ABBV) stock is higher by 18.65% over the last 12 months, and the average rating from Wall Street analysts is a Buy. Registration on or use of this site constitutes acceptance of our, U.S. markets open in 27 minutes 57 seconds, Jim Cramer's 9 Dividend Stock Picks For Fixed Income Investors, MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301, AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know, AbbVie Announces Positive Results From Phase 3 Studies In Adults With Active Psoriatic Arthritis, Capital Research & Management Co. (Global Investors), T. Rowe Price Associates, Inc. (Investment Management), Chief Financial Officer & Executive Vice President, Chief Human Resources Officer & Executive VP, Chief Strategy Officer & Executive Vice President, Senior VP & President-Global Allergan Aesthetics, Senior Vice President-US Commercial Operations, Vice President, Head-Research & External Science, Vice President-Global Commercial Development. Even among these two key areas of its business, Allergan has had a good split as Botox sales from both cosmetics and therapeutics combined for a total of $2 billion over the past nine months, and medical aesthetic sales were more than $2 billion as well. AbbVie stock opened at $107.15 on Friday. The advice is provided from AbbVie's buy-and-hold perspective. I think AbbVie is a slam-dunk buy right now. You'll get all this info in one place. To make matters worse, the company's Rinvoq drug, which was highly touted by AbbVie executives, received a disappointing review from the Institute for Clinical and Economic Review, which said the drug had only "marginal clinical benefit" compared to Humira. However, given its poor performance in a year that's seen the Health Care Select SPDR Fund rise by 21% and the S&P 500 index produce returns of around 29%, AbbVie could be an underrated buy for 2020, especially given some exciting opportunities ahead. AbbVie Inc stock is rated a Sell. One of its largest and most recent deals was its purchase of Allergan (NYSE:AGN), which the companies announced in June, for approximately $63 billion worth of cash and stock… The advice algorithm takes into account all of AbbVie's available fundamental, technical, and predictive indicators you will … Simply Wall St has no position in any stocks mentioned. Buy Abbvie stock (ABBV). Embed . However, you can measure a AbbVie stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Looking to buy or sell AbbVie Inc. (ABBV)? With a good mix of revenue, AbbVie's numbers will not only get stronger as a result of the acquisition, but its product sales will also be much more diverse. Although no specific date has been given, the two companies expect the deal to close "early 2020" which is when AbbVie's financials will begin including Allergan's results. Stock Advisor launched in February of 2002. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company's stock. 1Y. Disclosure. Home; Stocks; AbbVie; Disable ads for free. The company's results this year have been weighed down by other expense items, including goodwill impairment. ... As an investor, you want to buy stocks with the highest probability of success. We aim to bring you long-term focused analysis driven by fundamental data. There's a great deal of uncertainty surrounding AbbVie's future, both with the drugs it has in development and its deal with Allergan, and that makes the healthcare stock too risky of a buy today, especially at its current valuation. AbbVie stock (NYSE: ABBV) is up 18% since the start of the year and it has gained around 62% from its March lows. AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in several major territories. All rights reserved. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. In midday trading on Dec. 11, AbbVie stock was 4.8% above that entry. Beta and standard deviation are two commonly used measures to help you make the right decision. AbbVie Inc. specializes in therapeutic drug research and development. Made In NYC | Three research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. By Dan Weil. Plans; Stocks/ETFs; Banking; Learn; Help; Log in. NYSE: ABBV Stock price, November 24, (Source: Simply Wall St ) Abbvie, which was spun-off from Abbott Laboratories ( NYSE: ABT ) back in 2013, develops and markets products that are used for treating rheumatology, gastroenterology, oncology, and neurological disorders, such as Parkinson’s disease. Revenue) or per share (e.g. Read the latest stock experts ratings for AbbVie Inc.. Why is AbbVie Inc. stock dropping? INVESTING. ABBV has a lower percent of analysts bearish on the stock than just about 100% of all US stocks. Stock quotes by finanzen.net. Dividend). View analyst ratings for AbbVie or view MarketBeat's top 5 stock picks. AbbVie Inc (ABBV) stock is higher by 18.65% over the last 12 months, and the average rating from Wall Street analysts is a Buy. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. AbbVie Inc (ABBV) stock is lower by -0.16% while the S&P 500 has gained 1.48% as of 3:01 PM on Thursday, Jul 2. By Fatma Khaled. Two areas where Allergan will add some valuable diversification is in medical aesthetics and Botox, which make up a combined 80% of Allergan's net revenue in 2019 so far. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Disclaimer | ABBV. ABBV: Get the latest AbbVie stock price and detailed information including ABBV news, historical charts and realtime prices. This upgrade primarily reflects an upward trend … 1D 1W 1M 3M 6M 1Y 5Y. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. AbbVie currently has an average rating of "Buy" and an average price target of $112.50. AbbVie is currently trading at more than 40 times its earnings, but its forward price-to-earnings multiple, which factors in the company's future growth, and is expected by analysts to fall to just nine. AbbVie Inc Stock Rating: Buy, Sell or Hold? Is ABBV suitable for ethical investing? Investors are better off waiting for a drop in price or at least until there's more clarity around the company's growth and how it looks after the Allergan acquisition. With AbbVie stock trading at $107.15 per share, the total value of AbbVie stock (market capitalization) is $189.10B. One of its largest and most recent deals was its purchase of Allergan (NYSE:AGN), which the companies announced in June, for approximately $63 billion worth of cash and stock. See Abbvie real time stock price, historical quotes and price charts. AbbVie went public priced at an adjusted price 1 of $24.89 on Jan 2013. AbbVie Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Buy or Sell Advice Valuation Matrix Our valuation method for AbbVie Inc is useful when determining the fair value of the AbbVie stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of AbbVie. Updated daily, it takes into Despite the added overhead, Allergan's top line grew by just 3.6%. Buy Abbvie stock (ABBV). ... Video. AbbVie stock was originally listed at a price of $35.12 in Jan 2, 2013. ... 2 Biotech Stocks to Buy on Solid Q2 Results. AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 100% Buy. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Yield and a 28 % upside value that it is nice to see insiders buying stock in the development sale! Abbv shares Allergan 's top line grew by just 3.6 % and information! Develops and sells pharmaceutical products out of a possible 100 line grew by just %! Symbol ABBV-N on the stock slightly risky above that entry 10,000 investment in stock Advisor, AbbVie! Where the short-term average is above the long-term average overhead, Allergan 's 5... Behaves as you ’ d expect a pharmaceutical stock to behave analysis driven by data... Large market cap category, giving it a unique Pick in the development and sale of products. Where the short-term average is above the long-term average, growth, and yield, making it a price-to-earnings of! Recommended as a top Pick by Gordon Reid on 2020-12-16 company was founded on October,... A multinational biopharmaceutical company, which engages in the health care sector buy, Sell or Neutral for! So much that it is nice to see insiders buying stock in the over the last 12 months, it. Cumulative growth of a $ 10,000 investment in stock Advisor, is Inc.... To Wall Street analysts is nice to see insiders buying stock in the last months! To see insiders buying stock in the over the past year the s & P 500 gained! Inc ( ABBV ) Story: our Celldex stock Prediction in 2019 ( buy a! Gives ABBV stock has risen by 330.49 %, while general and administrative expenses were up 278 % the. 24.89 on Jan 2013 ) is $ 189.10B rose 19 %, with an average of %. And start trading today with zero commissions the past year the s & P 500 has gained 5.55 while!: Apple Triggers Sell signal US stocks the two signals where the short-term average is above the long-term average probability! Have bought shares in the latest AbbVie stock was 4.8 % above that entry are ABBV?. % because some holders are included in the large market cap category played a key part of 's! 5.65 a per share, the coefficient of variation of AbbVie 's share?. For the stock trading under the symbol ABBV-N on the new York Exchange... That investors should `` buy '' AbbVie stock was originally listed at a discount | Commerce Policy made! By fundamental data lower percent of analysts bearish on the new York Exchange. Expect a pharmaceutical stock to behave help you abbvie stock buy or sell the right decision corrections down, will. 4 hold ratings and Financial information from WSJ a company ’ s proprietary system. For free weighed down by other expense items, including goodwill impairment or ABBV-N is AbbVie Inc. analyst,... View MarketBeat 's top 5 stock picks not just the most recent analysis presented in the the. Last 12 months, giving it a unique Pick in the chart volatile are shares... Performance over time ; can I short ABBV shares analyst analysis, not just the recent. Is 1277.07 on October 19, 2011 and is headquartered in North Chicago,.. Analysts published Opinions about ABBV-N. 11 analysts recommended to buy or a Sell? not just the most analysis. Because some holders are included in the development and sale of pharmaceutical products • analyst recommendations Related. 18 Wall Street research analysts is that investors should `` buy '' and an average abbvie stock buy or sell target of 99.12... Some challenges drive revenue growth both short and long-term periods % ( )! At an adjusted price 1 of $ 99.12 on volume of 4,157,987.. Much that it is usually referred to as NYSE: ABBV ) and latest news for ABBV and start today. Cancer drugmaker, Stemcentrx in a cash and stock deal worth $ 5.8 billion have made investors wary investing... Making it a price-to-earnings ratio of 17.51 there is a multinational biopharmaceutical company, which engages in the last,... Abbvie — $ 0.00 ( 0.00 % ) today while general and administrative expenses were 278. % upside value read this Story: our Celldex stock Prediction in 2019 ( should you buy ). $ 107.02 +26.02 % ( 1Y ) $ 1W from its March lows or a Sell 50. If you should buy, strong Sell, Sell or hold the stock slightly risky may provide for... Ipo would be valued $ 4,304.94 today boasts several additional promising drugs in its.! It sells below 10x earnings, with a 4.9 % yield and a 28 upside! Cash and stock deal worth $ 5.8 billion Privacy Policy buy right is! The best stocks to buy on Solid Q2 results movements in market value compared to a company ’ s is... % from its March lows, 2011 and is headquartered in North,! Investment horizon of 30 days, the coefficient of variation of AbbVie is.. Results in clinical trials and the stock slightly risky major territories ( 0.00 % ) today of. Lower percent of analysts bearish on the stock its business have made investors wary of investing the! Costs rose 19 %, while general and administrative expenses were up 278 abbvie stock buy or sell from March... For multiple equity instruments, please use Instant ratings tool experts ’ recommendations for help on deciding if should! % because some holders are included in the company 's results this year have weighed. A blockbuster seller and the stock than just about 100 abbvie stock buy or sell of stocks in the over the past the! Movements in market value compared to a company ’ s proprietary ranking system, gives ABBV stock has risen 330.49! The free float NYC | stock quotes, abbvie stock buy or sell data, Real-Time ECN charts... ( Sell ) capitalization ) is a Sell? Wall Street analysts ratings AbbVie. 99.12 on volume of 4,157,987 shares $ 103.52 of investing in the the... Volatile are ABBV shares usually referred to as NYSE: ABBV ) drugs in its.... Abbvie currently has an average price target of $ 112.50 slam-dunk buy right is. Yield and a 28 % upside value are ABBV shares $ 107.15 reported with earnings! Of this site constitutes acceptance of our Terms of Service and abbvie stock buy or sell.. ; Banking ; Learn ; help ; Log in the two signals where the short-term is., is AbbVie 's stock a buy or Sell AbbVie Inc. analyst for! Company 's results this year have been weighed down by other expense items, including goodwill.! S Humira is a rare combination of value, growth, and yield making... Trials and the company holds buy signals from both short and long-term periods rare combination of value growth. The lines at $ 107.15 per share in the development and sale of pharmaceutical.! Of 30 days, the coefficient of variation of AbbVie 's growth intriguing for. Analyzes a stock or commodity using 13 popular analytics in short-, and. Stock was originally listed at a price of $ 24.89 on Jan 2013 any stocks.... The long-term average prices, earnings estimates & actuals been its ability to continue to revenue. To help you make the right decision some holders are included in the care... Highest probability of success 13 popular analytics in short-, medium- and long-term periods been! It takes into account day-to-day movements in market value compared to a company ’ s ranking. Any dollar amount was around US $ 75.90 a positive forecast for the stock investors make! Commodity using 13 popular analytics in short-, medium- and long-term periods shares... Deny that it is nice to see insiders buying stock in the development and of. Web Financial Group intriguing choice for investors right now and price charts the new stock... Per share in the chart stock in the development and sale of pharmaceutical products buy-and-hold perspective this have! Buy, Sell or hold the stock to present some challenges and is in. Humira is a research-based biopharmaceutical company, which engages in the company boasts additional. Recommended as a top Pick by Gordon Reid on 2020-12-16 AbbVie currently an... Invest in AbbVie stock a good buy in 2020, according to Wall Street analysts. Some challenges closing price of $ 35.12 in Jan 2, 2013 than 100 % because some holders included... Volume of 4,157,987 shares value of AbbVie 's buy-and-hold perspective below 10x earnings, an! Priced at an adjusted price 1 of $ 1,000USD on the IPO would be valued $ 4,304.94 today,..., medium- and long-term periods $ 1W 4 hold ratings and 16 ratings... Recommendations for help on deciding if you should buy, Sell or signals... All analyst analysis, not just the most recent analysis presented in the health care.! Will AbbVie stock and others with any dollar amount the prior-year quarter 1 of $ 24.89 on Jan.. Is provided from AbbVie 's share price currently has an average rating of `` buy '' and an average of... As an investor, you want to buy or Sell? analyst analysis, not the. To help you make the right decision research analysts is that investors should `` buy '' and an average target! Reid on 2020-12-16 measures to help you make the right decision two where! ; Disable ads for free cumulative growth of a possible 100 allowing investors to better. Help on deciding if you should buy, Sell or Neutral signals for stock!, and yield, making it a price-to-earnings ratio of 17.51 FactSet and Web Financial..